HAB Pharma and Signature Phytochemicals have completed a merger through a slump sale, bringing both companies under a single consolidated entity. Finalized in March 2026, the merger was undertaken to streamline operations, harmonize corporate systems, and strengthen governance. The consolidated turnover is approximately Rs600 crore after accounting for intercompany sales.
HAB Pharmaceuticals, established in 1991, is an Indian pharmaceutical company engaged in the manufacturing of products across multiple therapeutic areas, including antibiotics, NSAIDs, and cardiovascular drugs. Signature Phytochemical Industries, established in 2016, manufactures and exports pharmaceutical tablets, capsules, and creams. The merger expands the combined entity’s manufacturing, research, and development capabilities, with a focus on specialty drugs for oncology, autoimmune disorders, chronic conditions, and rare diseases. The merged entity is also targeting markets in Latin America, Central Asia, and Southeast Asia.
HAB Pharmaceuticals is commissioning two new manufacturing plants: a sterile facility for semaglutide, prefilled syringes, injectables, vials, and lyophilized products, and a fully automated closed-loop oral solid dosage (OSD) plant. Both plants are expected to commence commercial production by August 2026.
The facilities are intended to increase production capacity, support regulatory approvals, and expand the company’s presence in Southeast Asia, Latin America, and Africa, where it has undergone regulatory audits in Uganda, Tanzania, and Iraq.
Saurabh Agarwal, Director at HAB Pharma said in a statement,“This merger marks a pivotal moment for our company. By consolidating our operations with Signature and strengthening our manufacturing capacities, we are now positioned for substantial growth. Our focus on innovation, niche products, and increasing our export and R&D capabilities will solidify the company’s position in the pharmaceutical industry, differentiating us through a diversified portfolio and a rapid go-to-market strategy. The new plants will provide us with the capacity to meet rising demand for complex and high-quality pharmaceutical products. Together, we will continue to lead in biologics, personalized medicine, and specialty generics by leveraging advanced R&D and innovative drug delivery systems.
Urvee Garg, Director at HAB Pharma, also shared her thoughts on the merger and the company’s growth trajectory, “This merger represents the next chapter in HAB Pharma’s growth story. We are focused on creating a more cohesive organization that can better serve both our domestic and international markets. With a solid foundation in manufacturing, a commitment to quality, and a focus on affordability, we are confident that HAB Pharma will continue to thrive and deliver innovative healthcare solutions across the world.”
Source: Economic Times